TGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TG Therapeutics Inc (TGTX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong revenue growth, recent capital infusion, expanded stock buyback program, and positive sentiment from institutional investors like ACT Capital Management indicate confidence in its future performance. While there are some minor concerns regarding declining net income and EPS, the overall outlook remains favorable for long-term growth.
The MACD is positive and expanding (0.188), indicating bullish momentum. RSI is neutral at 59.137, and moving averages are converging, suggesting a potential breakout. The stock is trading near its pivot level of 29.455, with resistance at 31.637 and support at 27.274.
TG Therapeutics secured a $750 million credit facility with potential access to $1 billion, enhancing its R&D and strategic investment capabilities.
The company expanded its stock buyback program from $100 million to $300 million, signaling confidence in its future.
ACT Capital Management's acquisition of a significant stake indicates institutional confidence.
Revenue nearly doubled YoY in 2025, with a strong 2026 revenue forecast of $875M-$900M.
Net income and EPS declined slightly YoY in Q4 2025, which could be a concern for profitability.
Gross margin dropped by 6.51%, indicating potential cost pressures.
Analyst sentiment is mixed, with JPMorgan maintaining an Overweight rating but lowering the price target, and BofA maintaining an Underperform rating despite raising the price target.
In Q4 2025, revenue increased by 78% YoY to $192.57M, showcasing strong growth. However, net income dropped by 1.26% YoY to $23.04M, and EPS declined by 6.67% YoY to 0.14. Gross margin also decreased to 80.19%, down 6.51% YoY.
Analyst sentiment is mixed. JPMorgan lowered its price target from $49 to $46 but maintained an Overweight rating. BofA raised its price target from $13 to $15 but kept an Underperform rating. Analysts highlight positive data catalysts and improving biotech sentiment but express concerns about sustainability.
